Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 14/20 | 0.87 |
| ▸ | CTSL | P07711 | 3/20 | 0.87 |
| ▸ | CTSB | P07858 | 3/20 | 0.87 |
| ▸ | LMNA | P02545 | 1/20 | 0.87 |
| ▸ | CTSG | P08311 | 1/20 | 0.87 |
| ▸ | CAPN9 | O14815 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aloxistatin SCHEMBL21981208 | 0.93 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL12620387 | 0.93 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL21981210 | 0.93 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL254426 | 0.93 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL483320 | 0.93 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL18498407 | 0.93 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL16982461 | 0.88 | CAPN1 (0.83) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL25901378 | 0.87 | CAPN1 (0.81) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL31406924 | 0.87 | CAPN1 (0.81) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL12653864 | 0.87 | CAPN1 (0.83) | CAPN1CTSLCTSBLMNACTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200237849-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200237849-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | APP, BACE1, PTMS | CAPN1 1955/4885CTSL 82/4885CTSB 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.